For millions of women living with endometriosis, persistent pain can disrupt daily life, affect fertility and limit treatment choices. Existing hormonal therapies may provide relief but can cause significant side effects, highlighting the need for al... Read more
Ambrose Healthcare’s acquisition of AM-Pharma, valued at up to €161 million plus royalties, strengthens its rare disease pipeline and establishes its first European base in the Netherlands. The deal adds ilofotase alfa, an investigational ... Read more
Biopharma Boardroom speaks with Hubert Martens, CEO of Salvia BioElectronics, about the development of the MySalvia System, an investigational implantable neuromodulation therapy for people living with resistant migraine. Martens discusses the techno... Read more
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a priority for drug developers. Axplora is addressing these challenges through Axotecan, its initiat... Read more
ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, announced the successful completion of the second close of its seed financing round, securing an additional €1.6 million, bringing... Read more
Lonza, a global contract development and manufacturing organization, to acquire the CDMO business of Merck Transaction sharpens the focus of Merck’s Life Science business sector and provides the CDMO business with a strong platform for its... Read more
NanoImaging Services, a cryo-EM CRO, and Proteos, a protein production research partner, have announced the launch of TrueCourse Biosciences, an integrated CRO that brings together advanced capabilities to help pharmaceutical and biotechnolog... Read more
As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of therapies must be designed from the outset with potency, manufacturability, scalability, analytical... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
